The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 701–800 of 1,002
Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice
Alsuliman, T., Marjanovic, Z., Rimar, D., Tarte, K., Avčin, T., Hagen, M., Schett, G. A., & Farge, D. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103687 · Cited by 20
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines
Li, Y., Xu, Y., Su, W., Xu, J., Ye, Z., Wang, Z., Liu, Q., & Chen, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117897 · Cited by 18
Applications of mRNA Delivery in Cancer Immunotherapy
Pan, X., Zhang, Y.-W.-Q., Dai, C., Zhang, J., Zhang, M., & Chen, X. X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s500520 · Cited by 19
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines
Meng, S., Hara, T., Miura, Y., Arao, Y., Saito, Y., Inoue, K., Hirotsu, T., Vecchione, A. M., Satoh, T., & Ishii, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073119 · Cited by 23
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics
Xu, M., & Xu, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02309-7 · Cited by 20
Reimagining drug nanocarriers: clinical realities and smarter strategies for targeted drug delivery
Baker, A., & Fruk, L. (2025) · Materials Horizons · doi:10.1039/d5mh00927h · Cited by 18
Yin, L., Zhou, S., Zhang, H., Shang, Y., Wu, S., & Jin, T. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1619597 · Cited by 19
In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
Huang, Y., Cao, R. Y., Wang, S., Chen, X., Yü, P., & Zhang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2558403 · Cited by 19
Pancreatic cancer in 2025: Have we found a solution?
Tonini, V., & Zanni, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i43.111433 · Cited by 23
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases
Chen, X., Liu, K., Liu, B., Li, S., Wang, Y., Du, X., Weng, J., Song, B., Wu, K., & Lai, P. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01769-0 · Cited by 19
Wen, P., Ai, Q., Fan, X., Gu, Z., 陈波, & Qian, H. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218257 · Cited by 20
CAR-T-Cell Therapy: Present Progress and Future strategies
Abbasi, M. H., Riaz, A., Khawar, M. B., Farooq, A., Majid, A., & Sheikh, N. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i2.726 · Cited by 18
A Mathematical Model for On-Target Off-Tumor Effect of CAR-T Cells on Gliomas
Santurio, D. S., & Barros, L. R. C. (2022) · Frontiers in Systems Biology · doi:10.3389/fsysb.2022.923085 · Cited by 18
Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment
Sadowski, K. A., Olejarz, W., & Basak, G. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315006 · Cited by 19
Gastric Cancer and the Immune System: The Key to Improving Outcomes?
Keshavjee, S., Moy, R. H., Reiner, S. L., Ryeom, S. W., & Yoon, S. S. (2022) · Cancers · doi:10.3390/cancers14235940 · Cited by 17
The ageing immune system as a potential target of senolytics
Du, P. Y., Gandhi, A., Bawa, M., & Gromala, J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad004 · Cited by 20
Chen, M., Jiang, J., & Hou, J. (2023) · Biomarker Research · doi:10.1186/s40364-023-00502-8 · Cited by 19
Saito, A., Kitayama, J., Nagai, R., & Aizawa, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061664 · Cited by 19
Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
Monzó, H. J., Hyytiäinen, M. M., Elbasani, E., Kalander, K., Wall, J., Moyano‐Galceran, L., Ramanathan, J. T., Jukonen, J., Laakkonen, P. M., Ristimaki, A. P., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0008 · Cited by 18
Heim, C., Moser, L. M., Kreyenberg, H., Bonig, H. B., Tonn, T., Wels, W. S., Gradhand, E., Ullrich, E., Meister, M. T., Koerkamp, M. J. A. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228894 · Cited by 18
Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment
He, X., Lan, H., Jin, K., & Liu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237764 · Cited by 18
Fyfe, J., Dye, D. E., Razak, N. B. A., Metharom, P., & Falasca, M. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.004 · Cited by 18
Falcone, N., Ermis, M., Gangrade, A., Choroomi, A., Young, P., Mathes, T. G., Monirizad, M., Zehtabi, F., Mecwan, M. M., Rodriguez, M., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202309069 · Cited by 18
Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
Hu, M., Liao, X., Yi, T., & Chen, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285113 · Cited by 19
A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy
Lee, I. K., Sharma, N., Noguera-Ortega, E., Liousia, M., Baroja, M. L., Etersque, J. M., Pham, J. M., Sarkar, S., Carreno, B. M., Linette, G. P., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.020 · Cited by 20
Inflammatory Network of Liver Fibrosis and How It Can Be Targeted Therapeutically
Lowe, K., Tanase, C. E., Maghami, S., Fisher, L. E., & Ghaemmaghami, A. M. (2023) · Immuno · doi:10.3390/immuno3040023 · Cited by 19
Functional Nucleic Acid-Based Immunomodulation for T Cell-Mediated Cancer Therapy
Wu, H., Lin, J., Ling, N., Zhang, Y., He, Y., Qiu, L., & Tan, W. (2023) · ACS Nano · doi:10.1021/acsnano.3c09861 · Cited by 18
Consideration of SHP-1 as a Molecular Target for Tumor Therapy
Lim, S., Lee, K. W., Kim, J. Y., & Kim, K. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010331 · Cited by 18
Ku, K. S., Tang, J., Chen, Y., & Shi, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105361 · Cited by 18
Advances in nano-immunotherapy for hematological malignancies
Xu, J., Liu, W., Fan, F., Zhang, B., Sun, C., & Hu, Y. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00525-3 · Cited by 21
Recent advances in understanding the immune microenvironment in ovarian cancer
Chen, J., Yang, L., Ma, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412328 · Cited by 18
Malarvannan, M., Ravichandiran, V., & Paul, D. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.465226 · Cited by 19
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
Taheri, M. M., Javan, F., Poudineh, M., & Athari, S. S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05534-8 · Cited by 21
Panuccio, G., Correale, P., D’Apolito, M., Mutti, L., Giannicola, R., Pirtoli, L., Giordano, A., Labate, D., Macheda, S., Carabetta, N., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01077-7 · Cited by 18
Emerging and Biological Concepts in Pediatric High-Grade Gliomas
Yoel, A., Adjumain, S., Liang, Y., Daniel, P. M., Firestein, R., & Tsui, V. (2024) · Cells · doi:10.3390/cells13171492 · Cited by 19
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment
Chen, Q., Sun, Y., & Li, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-01159-x · Cited by 17
Tuyết, N. T., & Youn, Y. S. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202426047 · Cited by 17
Garemilla, S. S. S., Gampa, S. C., & Garimella, S. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-02754-w · Cited by 19
Gamboa, L., Zamat, A. H., Thiveaud, C., Lee, H. J., Kulaksizoglu, E., Zha, Z., Campbell, N., Chan, C. S., Fábrega, S., Oliver, S. A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00968-5 · Cited by 25
Nishimoto, K. P., Lamture, G., Chanthery, Y. H., Teague, A., Verma, Y., Au, M., Smith‐Boeck, M., Salum, M., Murthy, P., Gundurao, S. R. Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011704 · Cited by 17
Edmonds, K. K., Wilkinson, M. E., Strebinger, D., Chen, H., Lash, B., Schaefer, C. C., Zhu, S., Liu, D., Zilberzwige‐Tal, S., Ladha, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61321-z · Cited by 17
Understanding and improving vaccine efficacy in older adults
Hofer, S. J., Rapp, S., Klenerman, P., & Simon, A. K. (2025) · Nature Aging · doi:10.1038/s43587-025-00939-6 · Cited by 23
Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy
Olawade, D. B., Oisakede, E. O., Egbon, E., Ovsepian, S. V., & Boussios, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080653 · Cited by 20
Liu, L., Li, Y., Li, H., Shang, T., & Liu, L. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5824 · Cited by 19
The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Nuvvula, S., Dahiya, S., & Patel, S. A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.010 · Cited by 17
Gao, L., Zhang, A., Yang, F., & Du, W. (2022) · Vaccines · doi:10.3390/vaccines10081272 · Cited by 17
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
Fanciulli, G., Modica, R., Salvia, A. L., Campolo, F., Florio, T., Mikovic, N., Plebani, A., Vito, V. D., Colao, A., & Faggiano, A. (2022) · Cancers · doi:10.3390/cancers14163991 · Cited by 17
Bozzer, S., Bo, M. D., Grimaldi, M. C., Toffoli, G., & Macor, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091965 · Cited by 17
The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
Shevyrev, D., Tereshchenko, V., & Sennikov, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314728 · Cited by 19
Activation of cancer immunotherapy by nanomedicine
Wang, L., Xu, H., Weng, L., Sun, J., Jin, Y. H., & Xiao, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1041073 · Cited by 18
Matteis, S. D., Dicataldo, M., Casadei, B., Storci, G., Laprovitera, N., Arpinati, M., Maffini, E., Cortelli, P., Guarino, M., Vaglio, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058126 · Cited by 17
Neo, S., Xu, S., Chong, J., Lam, K., & Wu, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006434 · Cited by 19
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Yang, Z., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002549 · Cited by 18
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18
Targeting Macrophages for Tumor Therapy
Wang, Y., Barrett, A., & Hu, Q. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00845-y · Cited by 18
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
Xu, Y., Liu, Y., Ge, Y., Li, H., Zhang, Y., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1230824 · Cited by 17
Alayoubi, A. M., Khawaji, Z. Y., Mohammed, M. A., & Mercier, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05457-2 · Cited by 24
Delivery of mRNA for cancer therapy: progress and prospects
Su, L.-J., Xu, M.-X., Ji, Z.-H., Zhu, J.-Q., Yu, M., Wang, Y., & Lin, Y. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102013 · Cited by 17
Application of exosomes as nanocarriers in cancer therapy
Hu, J., Zhu, J., Chai, J., Zhao, Y., Luan, J., & Wang, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01991h · Cited by 17
Living Cell‐Derived Intelligent Nanobots for Precision Oncotherapy
Zhou, L., Li, K., Liu, Y., Zhang, R., Yao, Y., Chen, Q., Xie, D., & Zhang, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202311857 · Cited by 17
Zhao, J., Wei, C., Wang, S., Zhang, Y., Wang, W., Zhao, D., Wang, Z., Zhou, Z., Bai, J., Zhang, W., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00958-9 · Cited by 17
Önder, C. E., Moustafa-Oglou, M., Schröder, S. M., Hartkopf, A. D., Koch, A., & Seitz, C. M. (2023) · Cancers · doi:10.3390/cancers16010168 · Cited by 17
The significance of targeting lysosomes in cancer immunotherapy
Xu, Y., Shao, B., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1308070 · Cited by 21
Ajayi-Nifise, A. O., Olubusola, O., Falaiye, T., Mhlongo, N. Z., & Daraojimba, A. I. (2024) · Finance & Accounting Research Journal · doi:10.51594/farj.v6i2.787 · Cited by 17
Biophysical and biochemical aspects of immune cell–tumor microenvironment interactions
Benmelech, S., Le, T., McKay, M., Nam, J., Subramaniam, K. V., Tellez, D., Vlasak, G., & Mak, M. (2024) · APL Bioengineering · doi:10.1063/5.0195244 · Cited by 19
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy
Huang, J., Yang, Q., Wang, W., & Huang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378739 · Cited by 18
Targeting apoptosis in clear cell renal cell carcinoma
Kowalewski, A., Borowczak, J., Maniewski, M., Gostomczyk, K., Grzanka, D., & Szylberg, Ł. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116805 · Cited by 18
Pavlovic, K., Carmona-Luque, M. D., Corsi, G. I., Maldonado‐Pérez, N., Molina-Estévez, F. J., Peralbo‐Santaella, E., Cortijo-Gutierréz, M., Justicia-Lirio, P., Tristán‐Manzano, M., Ronco-Díaz, V., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401683 · Cited by 17
Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment
Sood, A., Jothiswaran, V. V., Singh, A., & Sharma, A. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00264 · Cited by 17
Novel immunotherapeutic approaches in gastric cancer
Yang, M., Lin, W., Huang, J., Mannucci, A., & Luo, H. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae020 · Cited by 17
Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors
Stilpeanu, R. I., Secara, B. S., Cretu-Stancu, M., & Bucur, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011127 · Cited by 17
Ramalingam, P. S., Premkumar, T., Sundararajan, V., Hussain, M. S., & Arumugam, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01455-6 · Cited by 18
Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?
Bukowski, K., Rogalska, A., & Marczak, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211927 · Cited by 18
Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment
Jiang, D., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1590781 · Cited by 17
NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
Sentí, M. E., Ceccaldi, A., Luciani, M., Saber, N., Schürmann, P. J. L., Geerlings, M. W., Hölig, P., de Beer, J., Hannus, M., Campbell, F., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1458636 · Cited by 17
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 18
Lesch, S., Nottebrock, A., Rataj, F., Heise, C., Endres, S., & Kobold, S. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00747-9 · Cited by 17
Trani, C. A. D., Cirella, A., Arrizabalaga, L., Bella, Á., Fernández-Sendin, M., Russo-Cabrera, J. S., Gomar, C., Olivera, I., Bolaños, E., González-Gomariz, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2147317 · Cited by 17
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 18
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Zhou, X., Hu, S., & Wang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101599 · Cited by 16
Structural Mechanisms of Topoisomerase-Targeting Drugs
O'Donnell, A. C., & Berger, J. M. (2025) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030122-043917 · Cited by 16
Kim, H. J., Jang, M., & Kim, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104863 · Cited by 16
Lau, P., Liang, L., Chen, X., Zhang, J., & Liu, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103362 · Cited by 19
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
Wei, D., Wang, L., Liu, Y., Zuo, X., Shen, X., & Bresalier, R. S. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1201 · Cited by 18
Xiang, S., Zhan, H., Zhan, J., Li, X., Lin, X., & Sun, W. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100400 · Cited by 16
Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions
Böldicke, T. W. (2022) · Antibodies · doi:10.3390/antib11030049 · Cited by 18
Cancer cell targeting by CAR-T cells: A matter of stemness
D’Accardo, C., Porcelli, G., Mangiapane, L. R., Modica, C., Pantina, V. D., Roozafzay, N., Franco, S. D., Gaggianesi, M., Veschi, V., Iacono, M. L., et al. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1055028 · Cited by 16
Akter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 17
Immune modulations of the tumor microenvironment in response to phototherapy
Valerio, T. I., Furrer, C. L., Sadeghipour, N., Patrock, S.-J. X., Tillery, S. A., Hoover, A. R., Liu, K., & Chen, W. R. (2023) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545823300070 · Cited by 16
Cancer Cell Culture: The Basics and Two-Dimensional Cultures
Tutty, M. A., Holmes, S., & Prina‐Mello, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3056-3_1 · Cited by 17
Wang, L., Wang, X., Wu, Y., Wang, J., Zhou, W., Wang, J., Guo, H., Zhang, N., Zhang, L., Hu, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216303 · Cited by 16
He, M., Zhang, D., Cao, Y., Chi, C., Zeng, Z., Yang, X., Yang, G., Sharma, K., Hu, K., & Enikeev, M. E. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19147 · Cited by 16
Singh, M., Brööks, A. G., Toofan, P., & McLuckie, K. (2023) · Gene Therapy · doi:10.1038/s41434-023-00417-x · Cited by 16
Nanobodies: A Game-Changer in Cell-Mediated Immunotherapy for Cancer
Mustafa, M. I., & Mohammed, A. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.08.008 · Cited by 16
Role of immunotherapy in chondrosarcoma: A case report and review of the literature
Cohen-Nowak, A. J., Dressler, D. B., Rock, A., Mojica, K., Woo, D., Zuckerman, L. M., Chow, W., & Agulnik, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231199877 · Cited by 16
Stoecklein, S., Wunderlich, S., Papazov, B., Winkelmann, M., Kunz, W. G., Mueller, K., Ernst, K., Stoecklein, V. M., Blumenberg, V., Karschnia, P., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad135 · Cited by 16
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
Chamorro, D. F., Somes, L. K., & Hoyos, V. (2023) · Cancers · doi:10.3390/cancers16010124 · Cited by 20
Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management
Cong, Y., Devoogdt, N., Lambin, P., Dubois, L. J., & Yaromina, A. (2024) · Cancers · doi:10.3390/cancers16020371 · Cited by 16
Jiao, J.-Z., Zhang, Y., Zhang, W., He, M., Meng, M., Liu, T., Ma, Q., Xu, Y., Gao, P., Chen, C., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01260-5 · Cited by 16
Novel Clinical Trials and Approaches in the Management of Glioblastoma
Valerius, A. R., Webb, L. M., & Sener, U. T. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01519-4 · Cited by 17
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
